Tämä sivu käännettiin automaattisesti, eikä käännösten tarkkuutta voida taata. Katso englanninkielinen versio lähdetekstiä varten.

Tutkimus Fazirsiranista ihmisillä, joilla on ja ei ole maksaongelmia

keskiviikko 19. elokuuta 2026 päivittänyt: Takeda

Avoin, vaiheen 1 tutkimus farmakokinetiikkaa, turvallisuutta, siedettävyyttä ja farmakodynamiikkaa vasteena kerta-annos Fazirsiran (TAK-999) ihonalaiseen annokseen potilailla, joilla on tai ei ole maksan vajaatoimintaa

The main aim of this study is to learn how the body processes fazirsiran (pharmacokinetics [PK]) in people with mild, moderate, or severe liver problems, compared to people with normal liver function.

The study will include participants with liver scarring (cirrhosis) and mild, moderate, or severe liver problems, and participants with normal liver function. All participants will be given 1 injection of fazirsiran and will be followed up for 6 months after the fazirsiran injection.

Tutkimuksen yleiskatsaus

Tila

Valmis

Interventio / Hoito

Opintotyyppi

Interventio

Ilmoittautuminen (Todellinen)

34

Vaihe

  • Vaihe 1

Yhteystiedot ja paikat

Tässä osiossa on tutkimuksen suorittajien yhteystiedot ja tiedot siitä, missä tämä tutkimus suoritetaan.

Opiskelupaikat

      • Bratislava, Slovakia, 851 05
        • Summit Clinical Research s.r.o.
      • Malacky, Slovakia
        • Summit Clinical Research s.r.o.
      • Kistarcsa, Unkari, 2143
        • CRU Hungary Kft

Osallistumiskriteerit

Tutkijat etsivät ihmisiä, jotka sopivat tiettyyn kuvaukseen, jota kutsutaan kelpoisuuskriteereiksi. Joitakin esimerkkejä näistä kriteereistä ovat henkilön yleinen terveydentila tai aiemmat hoidot.

Kelpoisuusvaatimukset

Opintokelpoiset iät

18 vuotta - 85 vuotta (Aikuinen, Vanhempi Aikuinen)

Hyväksyy terveitä vapaaehtoisia

Joo

Sukupuolet, jotka voivat opiskella

Kaikki

Kuvaus

Inclusion Criteria:

Key Inclusion Criteria for All Participants

  • A 12-lead ECG at screening that, in the opinion of the investigator, has no abnormalities that compromise the participant's safety in this study.
  • No abnormal finding of clinical relevance at screening or before dosing that in the opinion of the investigator could adversely impact participant safety during the study or adversely impact study results.

Key Inclusion Criteria for Participants with Hepatic Impairment:

  • The participant is 18 to 75 years of age inclusive at the time of signing the informed consent form (ICF).
  • The participant has a body mass index (BMI) greater than or equal to (>=) 18.0 and less than or equal to (<=) 40.0 kilograms per square meter (kg/m^2) at screening.
  • Aside from HI, the participant must be sufficiently healthy for study participation based upon medical history, physical examination, vital signs, electrocardiograms (ECGs), and screening clinical laboratory profiles, as deemed by the investigator or designee.
  • Diagnosis of chronic (example, imaging, biopsy, etc.) stable hepatic insufficiency for at least 3 months before screening with features of cirrhosis due to any etiology according to medical history. HI must be stable, that is, no significant changes in hepatic function or clinical status in the 30 days preceding screening (or since the last visit if within 3 months before screening) and with treatment with stable doses of medication.
  • Has a Child-Turcotte-Pugh (CTP) score confirmed by 2 tests as follows:
  • Arm 1: Mild HI, CTP Class A: >=5 and <=6
  • Arm 2: Moderate HI, CTP Class B: >=7 and <=9
  • Arm 3: Severe HI, CTP Class C: >=10 and <=15
  • It must be confirmed that the participant does not have hepatocellular carcinoma (HCC).

Key Inclusion Criterion for Participants with Mild Hepatic Impairment • The participant has pulmonary status meeting criteria of percent predicted forced expiratory volume in the first second of expiration (ppFEV1) >=80 percent and percent predicted diffusing capacity of the lungs for carbon monoxide adjusted for hemoglobin (ppDLCOhgb) >=75%, based on pulmonary function test (PFT) at screening conducted as per American Thoracic Society (ATS)-European Respiratory Society (ERS) criteria.

Key Inclusion Criterion for Participants with Moderate and Severe Hepatic Impairment

• The participant has pulmonary status meeting the criteria defined in the protocol based on PFT at screening conducted as per ATS-ERS criteria.

Key Inclusion Criteria for Participants with Normal Hepatic Function

  • The participant is 18 to 85 years of age inclusive, at the time of signing the ICF.
  • The participant has a BMI >=18.0 and <=40.0 kg/m^2, at screening. Participants will be matched to participants with HI by BMI (±15%).
  • AAT level at or above the lower end of the reference range (above or equal to 16.6 micromole (mcM) or 90 milligram per deciliter [mg/dL]) at screening.
  • The participant has normal liver tests including alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), and total bilirubin (TBILI) <=1.2 x upper limit of the normal range (ULN) at screening and check-in.
  • The participant has pulmonary status meeting criteria of ppFEV1 >=80%, and ppDLCOhgb >=75%, based on PFT at screening conducted as per ATS- ERS criteria.

Exclusion Criteria:

Key Exclusion Criteria for All Participants:

  • The participant has uncontrolled hypertension (systolic blood pressure [BP] >170 mm Hg and diastolic BP >100 millimeter of mercury [mmHg] at screening). Participants may be rescreened once BP is successfully controlled.
  • The participant has a history of torsades de pointes, ventricular rhythm disturbances (example, ventricular tachycardia or fibrillation), heart block (excluding first-degree block, being pulse rate [PR] interval prolongation only), congenital long QT syndrome or new ST segment elevation or depression or new Q wave on ECG. Participants with a history of atrial arrhythmias should be discussed with the medical monitor.
  • The participant has symptomatic heart failure (per New York Heart Association guidelines) or severe heart failure with reduced ejection fraction (EF <20%), unstable angina, myocardial infarction, transient ischemic attack, or cerebrovascular accident within 6 months before screening.
  • The participant is expected to have severe and unavoidable high-level exposure to inhaled pulmonary toxins during the study.
  • The participant has had a recent lower respiratory tract infection, such as pneumonia, within the last 6 months before screening.
  • The participant has a history of malignancy within the last 1 year, except for adequately treated basal cell carcinoma, squamous cell skin cancer, superficial bladder tumors, or in situ cervical cancer. Participants with other curatively treated malignancies who have no evidence of metastatic disease and have been disease-free for >1 year may enter the study after approval by the medical monitor.
  • The participant has a history of thromboembolic disease (including deep vein thrombosis or pulmonary embolism) within 6 months of screening.

Key Exclusion Criteria for Participants with Hepatic Impairment:

  • The participant has a history of gastric or esophageal variceal bleeding within the past 6 months of dosing and for which varices have not been adequately treated with medication and/or endoscopic procedures.

  • The participant has grade >2 hepatic encephalopathy assessed using the West Haven criteria.

  • The participant has evidence of hepatopulmonary syndrome or portal-pulmonary hypertension.

  • The participant has portal vein thrombosis, transjugular intrahepatic portosystemic shunt (TIPS), or surgical portosystemic shunt.

  • The participant has required endoscopic treatment of esophageal or gastric varices or paracentesis to control ascites within the last 3 months of dosing.

  • The participant has chronic hepatitis B (hepatitis B surface antigen positive, or positive for both hepatitis B surface antibody and hepatitis B core antibody but negative for hepatitis B surface antigen); or has chronic or incompletely or unsuccessfully treated hepatitis C (as demonstrated by a positive hepatitis C antibody and positive polymerase chain reaction [PCR]).

  • The participant has any of the following clinically significant abnormal parameters at screening:

    • ALT or AST levels >250 units per liter (U/L) at screening.
    • Estimated glomerular filtration rate <45 milliliter per minute per 1.73 square meter (mL/min/1.73 m^2).

Opintosuunnitelma

Tässä osiossa on tietoja tutkimussuunnitelmasta, mukaan lukien kuinka tutkimus on suunniteltu ja mitä tutkimuksella mitataan.

Miten tutkimus on suunniteltu?

Suunnittelun yksityiskohdat

  • Ensisijainen käyttötarkoitus: Hoito
  • Jako: Ei satunnaistettu
  • Inventiomalli: Rinnakkaistehtävä
  • Naamiointi: Ei mitään (avoin tarra)

Aseet ja interventiot

Osallistujaryhmä / Arm
Interventio / Hoito
Kokeellinen: Arm 1, Mild HI: Fazirsiran 200 mg

Participants with mild hepatic impairment (HI) will receive fazirsiran 200 milligrams (mg) subcutaneous (SC) injection on Day 1.

Fazirsiran SC injection

Muut nimet:
  • TAK-999
Kokeellinen: Arm 2, Moderate HI: Fazirsiran 200 mg

Participants with moderate HI will receive fazirsiran 200 mg SC injection on Day 1. The dose may be modified after review of available safety and PK data by the sponsor study team in consultation with the investigator.

Fazirsiran SC injection

Muut nimet:
  • TAK-999
Kokeellinen: Arm 3, Severe HI: Fazirsiran 200 mg

Participants with severe HI will receive fazirsiran 200 mg SC injection on Day 1. The dose may be modified after review of available safety and PK data by the sponsor study team in consultation with the investigator.

Fazirsiran SC injection

Muut nimet:
  • TAK-999
Kokeellinen: Arm 4, Normal Hepatic Function: Fazirsiran 200 mg

Participants with normal hepatic function will receive fazirsiran 200 mg SC injection on Day 1. The dose may be modified after review of available safety and PK data by the sponsor study team in consultation with the investigator.

Fazirsiran SC injection

Muut nimet:
  • TAK-999

Mitä tutkimuksessa mitataan?

Ensisijaiset tulostoimenpiteet

Tulosmittaus
Toimenpiteen kuvaus
Aikaikkuna
Area Under the Plasma Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration (AUClast) of Fazirsiran
Aikaikkuna: Pre-dose, 0.25, 0.5, 1, 2, 3, 4, 5, 6, 9, 24, 48, 360, 1368, 2160 and 4320 hours post-dose

AUClast was defined as the area under the concentration-time curve from time 0 to the time of the last quantifiable concentration of fazirsiran in plasma.

Pre-dose, 0.25, 0.5, 1, 2, 3, 4, 5, 6, 9, 24, 48, 360, 1368, 2160 and 4320 hours post-dose
Area Under the Plasma Concentration-time Curve From Time 0 to Infinity (AUC0-inf) of Fazirsiran
Aikaikkuna: Pre-dose, 0.25, 0.5, 1, 2, 3, 4, 5, 6, 9, 24, 48, 360, 1368, 2160 and 4320 hours post-dose

AUC0-inf was defined as the area under the plasma concentration-time curve from time 0 extrapolated to infinity of fazirsiran in plasma.

Pre-dose, 0.25, 0.5, 1, 2, 3, 4, 5, 6, 9, 24, 48, 360, 1368, 2160 and 4320 hours post-dose
Maximum Observed Plasma Concentration (Cmax) of Fazirsiran
Aikaikkuna: Pre-dose, 0.25, 0.5, 1, 2, 3, 4, 5, 6, 9, 24, 48, 360, 1368, 2160 and 4320 hours post-dose

Cmax was defined as maximum observed concentration of fazirsiran in plasma.

Pre-dose, 0.25, 0.5, 1, 2, 3, 4, 5, 6, 9, 24, 48, 360, 1368, 2160 and 4320 hours post-dose

Toissijaiset tulostoimenpiteet

Tulosmittaus
Toimenpiteen kuvaus
Aikaikkuna
Number of Participants With Treatment-emergent Adverse Events (TEAEs)
Aikaikkuna: From the start of study drug administration up to follow-up (up to approximately 8 months)

An adverse event (AE) was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of the study intervention, whether or not the occurrence is considered related to the study intervention. A TEAE was defined as any event emerging or manifesting at or after the initiation of treatment with a study intervention or medicinal product or any existing event that worsened in either intensity or frequency following exposure to the study intervention or medicinal product.

From the start of study drug administration up to follow-up (up to approximately 8 months)
Number of Participants With Clinically Significant Abnormal Values for Laboratory Parameters
Aikaikkuna: From the first dose of study drug up to end of follow-up (up to approximately 8 months)

Laboratory parameters included serum chemistry, urinalysis, hematology and coagulation. Any abnormality in clinical laboratory results which were deemed clinically significant by the investigator were reported.

From the first dose of study drug up to end of follow-up (up to approximately 8 months)
Number of Participants With Clinically Significant Abnormal Values for Vital Signs Parameters
Aikaikkuna: From the first dose of study drug up to end of follow-up (up to approximately 8 months)

Vital signs included measurement of pulse rate, systolic and diastolic blood pressure, respiratory rate, body temperature and oxygen saturation. Any abnormality in vital signs which were deemed clinically significant by the investigator were reported.

From the first dose of study drug up to end of follow-up (up to approximately 8 months)
Number of Participants With Clinically Significant Abnormal Values for Electrocardiogram (ECG) Parameters
Aikaikkuna: From the first dose of study drug up to end of follow-up (up to approximately 8 months)

ECG parameters included heart rate, QRS intervals, QT intervals, PR intervals, RR intervals and QT intervals corrected for heart rate using Fridericia's formula (QTcF) intervals parameters measurement. Any abnormality in ECG assessments which were deemed clinically significant by the investigator were reported.

From the first dose of study drug up to end of follow-up (up to approximately 8 months)
Number of Participants With Clinically Significant Abnormal Values for Pulmonary Function Parameters
Aikaikkuna: From the first dose of study drug up to end of follow-up (up to approximately 8 months)

Pulmonary function was determined by diffusing capacity of the lungs for carbon monoxide (DLCO), forced expiratory volume in the first second (FEV1), forced vital capacity (FVC) and peak expiratory flow. Any abnormality in pulmonary function assessments which were deemed clinically significant by the investigator were reported.

From the first dose of study drug up to end of follow-up (up to approximately 8 months)
Number of Participants With Injection Site Reactions (ISRs) by Corresponding Toxicity
Aikaikkuna: From the first dose of study drug up to end of follow-up (up to approximately 8 months)

An ISR was defined as an adverse reaction (usually immunologic) developing at the site of injection. ISRs were recorded as AEs and graded using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 where, Grade 1: Mild; Grade 2: Moderate; Grade 3: Severe or medically significant but not immediately life-threatening; Grade 4: Life-threatening consequences; Grade 5: Death related to AE. Number of participants with ISRs, defined by the preferred terms (Injection site reaction, injection site haematoma and urticaria) with corresponding toxicity were reported. Injection site reaction and injection site haematoma are classified under the system organ class: General disorder, whereas Urticaria is classified under the skin and subcutaneous tissue disorders.

From the first dose of study drug up to end of follow-up (up to approximately 8 months)
Amount of Drug Excreted in Urine From Time 0 to Time 24 Hours (Ae0-24hrs) for Fazirsiran
Aikaikkuna: 0 to 24 hours post-dose

Ae0-24hrs was defined as the amount of study drug excreted in urine after 0-24 hours. Urine samples were collected at pre-specified intervals and Ae0-24hrs was assessed.

0 to 24 hours post-dose
Amount of Drug Excreted in Urine From Time 0 to Time 6 Hours (Ae0-6hrs) for Fazirsiran
Aikaikkuna: 0 to 6 hours post-dose

Ae0-6hrs was defined as the amount of study drug excreted in urine after 0-6 hours. Urine samples were collected at pre-specified intervals and Ae0-6hrs was assessed.

0 to 6 hours post-dose
Amount of Drug Excreted in Urine From Time 6 to Time 24 Hours (Ae6-24h) for Fazirsiran
Aikaikkuna: 6 to 24 hours post-dose

Ae6-24hrs was defined as the amount of study drug excreted in urine after 6-24 hours. Urine samples were collected at pre-specified intervals and Ae6-24hrs was assessed.

6 to 24 hours post-dose
Percentage of Recovered Drug in Urine Compared With the Dose (%Dose)
Aikaikkuna: 0 to 6, 6 to 9 and 9 to 24 hours post-dose

Percentage of recovered drug in urine (%Dose) was calculated as the amount of drug recovered in urine divided by administered dose*100.

0 to 6, 6 to 9 and 9 to 24 hours post-dose
Renal Clearance (CLr) for Fazirsiran
Aikaikkuna: 0 to 24 hours post-dose

Renal clearance for fazirsiran was reported.

0 to 24 hours post-dose
Absolute Change From Baseline in Serum Alpha-1 Antitrypsin (AAT) at Nadir
Aikaikkuna: Baseline, 8 weeks post-dose

Absolute change from baseline in serum AAT was calculated by subtracting the baseline value of AAT concentration from the value at the specified time point. Absolute change from baseline at 8 weeks post dose was reported.

Baseline, 8 weeks post-dose
Percent Change From Baseline in Serum AAT at Nadir
Aikaikkuna: Baseline, 8 weeks post-dose

Percent change from baseline serum AAT was calculated by subtracting the baseline value of AAT concentration from the value at the specified time points, dividing the result by the baseline value, and then multiplying by 100 to express it as a percentage. Percent change from baseline at 8 weeks post dose was reported.

Baseline, 8 weeks post-dose
Absolute Change From Baseline in Serum AAT
Aikaikkuna: Baseline, Days 15, 29 and 57

Absolute change from baseline in serum AAT was calculated by subtracting the baseline value of AAT concentration from the value at the specified time points.

Baseline, Days 15, 29 and 57
Percent Change From Baseline in Serum AAT
Aikaikkuna: Baseline, Days 15, 29 and 57

Percent change from baseline serum AAT was calculated by subtracting the baseline value of AAT concentration from the value at the specified time points, dividing the result by the baseline value, and then multiplying by 100 to express it as a percentage.

Baseline, Days 15, 29 and 57

Yhteistyökumppanit ja tutkijat

Täältä löydät tähän tutkimukseen osallistuvat ihmiset ja organisaatiot.

Sponsori

Tutkijat

  • Opintojohtaja: Study Director, Takeda

Julkaisuja ja hyödyllisiä linkkejä

Tutkimusta koskevien tietojen syöttämisestä vastaava henkilö toimittaa nämä julkaisut vapaaehtoisesti. Nämä voivat koskea mitä tahansa tutkimukseen liittyvää.

Opintojen ennätyspäivät

Nämä päivämäärät seuraavat ClinicalTrials.gov-sivustolle lähetettyjen tutkimustietueiden ja yhteenvetojen edistymistä. National Library of Medicine (NLM) tarkistaa tutkimustiedot ja raportoidut tulokset varmistaakseen, että ne täyttävät tietyt laadunvalvontastandardit, ennen kuin ne julkaistaan ​​julkisella verkkosivustolla.

Opi tärkeimmät päivämäärät

Opiskelun aloitus (Todellinen)

Torstai 5. lokakuuta 2023

Ensisijainen valmistuminen (Todellinen)

Keskiviikko 3. syyskuuta 2025

Opintojen valmistuminen (Todellinen)

Keskiviikko 3. syyskuuta 2025

Opintoihin ilmoittautumispäivät

Ensimmäinen lähetetty

Perjantai 26. toukokuuta 2023

Ensimmäinen toimitettu, joka täytti QC-kriteerit

Perjantai 26. toukokuuta 2023

Ensimmäinen Lähetetty (Todellinen)

Tiistai 6. kesäkuuta 2023

Tutkimustietojen päivitykset

Viimeisin päivitys julkaistu (Todellinen)

Maanantai 16. marraskuuta 2026

Viimeisin lähetetty päivitys, joka täytti QC-kriteerit

Keskiviikko 19. elokuuta 2026

Viimeksi vahvistettu

Lauantai 1. elokuuta 2026

Lisää tietoa

Tähän tutkimukseen liittyvät termit

Muut tutkimustunnusnumerot

  • TAK-999-1001
  • 2023-503735-17-00 (Ctis: EU CTIS)
  • 2023 (Yhdysvaltain NIH-apuraha/sopimus)

Yksittäisten osallistujien tietojen suunnitelma (IPD)

Aiotko jakaa yksittäisten osallistujien tietoja (IPD)?

JOO

IPD-suunnitelman kuvaus

Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.

IPD-jaon käyttöoikeuskriteerit

IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/ For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.

IPD-jakamista tukeva tietotyyppi

  • STUDY_PROTOCOL
  • MAHLA
  • ICF
  • CSR

Lääke- ja laitetiedot, tutkimusasiakirjat

Tutkii yhdysvaltalaista FDA sääntelemää lääkevalmistetta

Ei

Tutkii yhdysvaltalaista FDA sääntelemää laitetuotetta

Ei

Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .

Tilaa